IX BIOPHARMA - SGX Stock

{"summary": "The author highlights IX Biopharma's recent US government contract and progress toward an Emergency Use Authorization as potential growth catalysts.", "reason": "Author explicitly identifies IX Biopharma and gives own directional judgment with concrete catalysts (US government contract, EUA submission timeline).", "ideas": [{"symbol": "IXB.SI", "direction": "long", "thesis": "IX Biopharma has secured a $41 million sole-source contract from the US Defense Health Agency to fund Phase 3 trials and regulatory work. The company is currently pursuing an Emergency Use Authorization for its product, with a submission expected in Q4 2026. The primary risk is the execution of the regulatory process and the dependency on US government procurement.", "thesis_short": "US government contract and EUA progress drive potential growth for IX Biopharma.", "quote": "The EUA and US government contact looks to be a massive driver for it to move to the next stage.", "confidence": 0.8, "sentiment": 0.8, "timeframe": "Q4 2026"}], "model": "deepseek-v4-flash", "verified": true, "extraction_model": "gemini-3.1-flash-lite"}